The authors provide a summary of the pathology, the transcriptional profile and genetic and immune-phenotypic features of human angioimmunoblastic lymphoma (AITL). In addition, they give an overview of preclinical models that recapitulate more or less faithfully human AITL characteristics and pathology.
TG Therapeutics, Inc. announced that the FDA has accepted the company’s New Drug Application for umbralisib, the company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with previously treated marginal zone lymphoma who have received at least one prior anti-CD20 based regimen and follicular lymphoma who have received at least two prior systemic therapies.
[TG Therapeutics, Inc.]
BryoLogyx, Inc. announced that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute, to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia and lymphoma.
Scientists treated 14 relapsed or refractory diffuse large B-cell lymphoma patients by combining autologous hematopoietic stem cell transplantation and anti-CD19 chimeric antigen receptor T-cell therapy.
1254621 7W99HMR7 items 1 apa default asc 1
The authors analyzed 60 patients with diffuse large B cell lymphoma treated with FDA-approved CD19 chimeric antigen receptor (CAR) T cells and report the incidence, risk factors, and management of infections during the first year after treatment.
[Blood Cancer Journal]
6445212 FRPN9CDP items 1 apa default asc 1
Wudhikarn, K., Palomba, M. L., Pennisi, M., Garcia-Recio, M., Flynn, J. R., Devlin, S. M., Afuye, A., Silverberg, M. L., Maloy, M. A., Shah, G. L., Scordo, M., Dahi, P. B., Sauter, C. S., Batlevi, C. L., Santomasso, B. D., Mead, E., Seo, S. K., & Perales, M.-A. (2020). Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer Journal, 10(8), 1–11. https://doi.org/10.1038/s41408-020-00346-7 Cite
Researchers showed that LW-213 dose-dependently inhibited human cutaneous T-cell lymphoma cell lines with IC50 values of around 10 μM, meanwhile it potently inhibited primary leukemia cells derived from peripheral blood of T-cell lymphoma patients.
[Acta Pharmacologica Sinica]
6445212 JLV5JA2S items 1 apa default asc 1
Yu, X., Zhu, M., Wang, J., Li, H., Hu, P., Qing, Y., Wang, X., Wang, H., Wang, Z., Xu, J., Guo, Q., & Hui, H. (2020). LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK–eIF2α–ATF4–CHOP axis. Acta Pharmacologica Sinica, 1–11. https://doi.org/10.1038/s41401-020-0466-7 Cite
MorphoSys AG and Incyte announced that the FDA has approved Monjuvi in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.
Investigators showed that transient glucose restriction in activated CD8+ effector T cells metabolically primed effector functions and enhanced tumor clearance in mice.
6445212 CIWKI7P8 items 1 apa default asc 1
Klein Geltink, R. I., Edwards-Hicks, J., Apostolova, P., O’Sullivan, D., Sanin, D. E., Patterson, A. E., Puleston, D. J., Ligthart, N. A. M., Buescher, J. M., Grzes, K. M., Kabat, A. M., Stanczak, M., Curtis, J. D., Hässler, F., Uhl, F. M., Fabri, M., Zeiser, R., Pearce, E. J., & Pearce, E. L. (2020). Metabolic conditioning of CD8 + effector T cells for adoptive cell therapy. Nature Metabolism, 1–14. https://doi.org/10.1038/s42255-020-0256-z Cite
The authors report here a patient with adult T‐cell leukemia/lymphoma, who developed paroxysmal nocturnal hemoglobinuria seven years after umbilical cord blood transplantation.
[European Journal of Haematology]
1254621 62HJFY6I items 1 apa default asc 1
Kite announced that the FDA has granted accelerated approval to Tecartus™, the first and only approved chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
[Gilead Sciences, Inc.]
Analysis of a rare clinical sample of EBV-positive DLBCL, in combination with a NOD/SCID mouse xenograft model, confirmed the effect of IL-21 on the proliferation of EBV-positive diffuse large B cell lymphoma cells.
Investigators assessed the hematopoietic stem cell content within the CD34+ fraction of graft samples from three groups of patients: 1-Good Mobilizer patients receiving G-CSF only, 2-Poor Mobilizer (PM) patients receiving G-CSF only, 3-PM patients receiving G-CSF + Plerixafor.
1254621 84W74789 items 1 apa default asc 1